AZTA

Azenta Inc

Add to Watchlist

Advanced Chart

30.810

+1.6(5.478%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

30.890

Open

29.610

VWAP

30.26

Vol

92.19K

Mkt Cap

1.34B

Low

29.610

Amount

2.79M

EV/EBITDA(TTM)

28.22

Total Shares

53.92M

1.02B

EV/OCF(TTM)

12.18

P/S(TTM)

2.02

Azenta, Inc. is a provider of life sciences solutions worldwide. The Company provides a full suite of cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions globally. The Company's segments include Sample Management Solutions and Multiomics. Its Sample Management Solutions segment offers end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Company's Multiomics segment includes its genomic services business, which advances research and development activities by providing gene sequencing, synthesis, editing and related services. The Company's brands include GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

Unlock Winning Stocks with Intellectia.AI

Trusted by 300K+ investors. Get AI-driven trading signals to seize opportunities fast!

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

149.91M

+4.53%

0.170

+240%

154.55M

+4.78%

0.190

+137.5%

157.32M

-7.49%

0.200

+11.11%

Estimates Revision

The market is revising Upward the revenue expectations for Azenta, Inc. (AZTA) for FY2025, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by 10.43%.

Revenue Estimates for FY2025

Revise Upward

+0.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.38%

In Past 3 Month

Stock Price

Go Up

+10.43%

In Past 3 Month

5 Analyst Rating

11.65% Upside

Wall Street analysts forecast AZTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZTA is 34.40 USD with a low forecast of 30.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

0 Sell

Hold

11.65% Upside

Current: 30.810

Low

30.00

Averages

34.40

High

40.00

11.65% Upside

Current: 30.810

Low

30.00

Averages

34.40

High

40.00

Raymond James

Market Perform

Outperform

upgrade

$35

2025-08-06

Reason

Raymond James

Price Target

$35

2025-08-06

upgrade

Market Perform

Outperform

Reason

Raymond James upgraded Azenta to Outperform from Market Perform with a $35 price target. While the Q3 print was \"noisy,\" it drove the stock to a level that the firm believes will be a bottom, the analyst tells investors in a research note. Raymond James views the Q3 results as a clearing event and is hopeful that \"reasonable\" performance going forward, especially if/when the end market improves, supports a return to more reasonable multiples.

Evercore ISI

Vijay Kumar

In Line

downgrade

$35 -> $33

2025-08-05

Reason

Evercore ISI

Vijay Kumar

Price Target

$35 -> $33

2025-08-05

downgrade

In Line

Reason

Evercore ISI analyst Vijay Kumar lowered the firm's price target on Azenta to $33 from $35 and keeps an In Line rating on the shares. Macro uncertainty that led to order pushouts and Q4 guidance are weighing on the stock, says the analyst, who adds that the Street is "questioning the 4Q visibility" given macro uncertainty.

Stephens

initiated

$35

2025-07-21

Reason

Stephens

Price Target

$35

2025-07-21

initiated

Reason

Stephens resumed coverage of Azenta with an Equal Weight rating and $35 price target. While "encouraged" by the new management team's efforts to streamline the portfolio and believing that there is "a lot of room for improvement on the margin side," the firm prefers to take more of a "wait-and-see approach" until the macro overhang improves, the analyst tells investors.

Needham

David Saxon

Strong Buy

Maintains

$55 → $59

2025-02-06

Reason

Needham

David Saxon

Price Target

$55 → $59

2025-02-06

Maintains

Strong Buy

Reason

Evercore ISI Group

Vijay Kumar

Hold

Maintains

$50 → $52

2025-02-06

Reason

Evercore ISI Group

Vijay Kumar

Price Target

$50 → $52

2025-02-06

Maintains

Hold

Reason

Stephens & Co.

Jacob Johnson

Buy

Reiterates

$60

2025-01-02

Reason

Stephens & Co.

Jacob Johnson

Price Target

$60

2025-01-02

Reiterates

Buy

Reason

Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), Alignment Healthcare (ALHC), Privia Health (PRVA), Vulcan Materials (VMC), South State (SSB), Matson (MATX), Azenta (AZTA), Prog Holdings (PRG), Carvana (CVNA), Blueprint Medicines (BPMC), Truist Financial (TFC), Cognex (CGNX), Fiserv (FI), Hancock Whitney (HWC), SunOpta (STKL), Wingstop (WING), SM Energy (SM), The Andersons (ANDE) and Bank of Marin (BMRC).

See All Ratings

Valuation Metrics

The current forward P/E ratio for Azenta Inc (AZTA.O) is 36.58, compared to its 5-year average forward P/E of 188.61. For a more detailed relative valuation and DCF analysis to assess Azenta Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

188.61

Current PE

36.58

Overvalued PE

489.66

Undervalued PE

-112.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

36.28

Current EV/EBITDA

9.52

Overvalued EV/EBITDA

62.38

Undervalued EV/EBITDA

10.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.61

Current PS

2.09

Overvalued PS

8.57

Undervalued PS

2.65

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Intellectia.AI: Fast-Track Your Stock Wins

Loved by 300K+ users. Get precise AI signals to ride market trends in minutes!

Financials

Annual

Quarterly

FY2025Q3

YoY :

-0.24%

143.94M

Total Revenue

FY2025Q3

YoY :

-100.74%

40.00K

Operating Profit

FY2025Q3

YoY :

-530.38%

680.00K

Net Income after Tax

FY2025Q3

YoY :

+858.33%

-1.15

EPS - Diluted

FY2025Q3

YoY :

-411.77%

14.97M

Free Cash Flow

FY2025Q3

YoY :

+3.72%

47.07

Gross Profit Margin - %

FY2025Q3

YoY :

+32.62%

6.83

FCF Margin - %

FY2025Q3

YoY :

-527.27%

0.47

Net Margin - %

FY2025Q3

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

69.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

201.4K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

123.6K

Volume

Months

6-9

619.1K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

16.0K

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

69.7K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

201.4K

USD

Months

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

Intellectia.AI: Your Edge in Stock Trading

Join 300K+ users and access AI-powered stock picks that spot trends in minutes!

AZTA News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

06:38:31

Azenta reports Q3 continuing operations EPS 19c, consensus 14c

2025-07-31 (ET)

2025-07-31

16:26:54

Azenta enters collaboration with Frenova

2025-05-13 (ET)

2025-05-13

16:23:46

Azenta, Form Bio announce strategic partnership

News

7.5

07-31PRnewswire

Azenta Life Sciences Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

7.5

07-31Newsfilter

Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

1.0

07-30PRnewswire

Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference